Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Delcath said it will reduce headcount by 20% and will focus on its clinical development program and European commercialization of its Hepatic
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury